STOCKS TELEGRAPH

Tag: Jounce Therapeutics

  • What Raised The Jounce (JNCE) Stock 5% Up In Extended Trading?

    As of last check in afterhours trading, Jounce Therapeutics Inc. (JNCE) was up 5.01% to trade at $7.75. During the regular session on Wednesday, shares of Jounce stock closed at $7.38, down 2.25 percent.

    On the day of trading, JNCE stock volumes were 0.72 million shares, a substantial increase over the 396.95K average daily volume over the past three months. Throughout the trading session, JNCE stock fluctuated between $7.315 and $7.75. The company is to host a virtual event this month, news that came to be raising the JNCE stock.

    What is the purpose of that event?

    With a biomarker-driven approach, Jounce is dedicated to transforming the treatment of cancer through immunotherapy therapies that enable the immune system to attack tumors and provide long-term benefits to patients.  Multiple JNCE development programs are currently underway while also advancing a number of translational science assets based on its robust discovery engine.

    Earlier today, Jounce announced it would host a virtual Research and Development Day.

    • The event will be held by JNCE on Wednesday, June 23, 2021, at 10:00 a.m. – 12:00 p.m. ET.
    • JNCE management and scientific team members will present, as well as key opinion leader and Jounce scientific founder Robert Schreiber, PhD, of The Washington University School of Medicine.
    • Those who are interested can access the webcast of the R&D Day by visiting the Investors and Media section of Jounce’s website under “Events and Presentations.”
    • A replay of the webcast will be available after the presentation for 30 days.

    Other developments:

    Jounce (JNCE) also announced this week that the US Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for JTX-1811, an anti-CCR8 antibody. The rights to develop and commercialize JNCE’s that antibody belong exclusively to Gilead Sciences, Inc. (Nasdaq: GILD). JNCE will receive a $25.0 million milestone payment upon IND clearance.

  • Jounce Therapeutics Inc [JNCE] Rallies after Gilead Deal – What Next?

    Jounce Therapeutics Inc [JNCE] Rallies after Gilead Deal – What Next?

    Jounce Therapeutics Inc [NASDAQ:JNCE] is a top performer this afternoon. After trading in a range all through August, the stock has gapped up and is in gains of close to 50%.

    This follows the company’s announcement that it was entering into an exclusive license agreement with Gilead Sciences for a novel immunotherapy program named JTX-1811.  JTX-1811 is a monoclonal antibody that depletes immunosuppressive tumour-infiltrating T cells. It is currently under development and will have an investigational new drug application in H1 of 2020.

    Commenting on the agreement, between the two companies, Jounce CEO Richard Murray stated that the investment that Gilead’s had made in the JTX-1811 program was a major boost to the company’s translational science program that is differentiated and focuses on sustainability in treating people with cancer but have not gained from immunotherapy.

    He added that the company’s mission was to give patients the best immunotherapy treatments and that it remained focused on offering long-terms solutions such as JTX-1811. On his part, Gilead executive Vice President stated that they were happy to add JTX-`1811 to the company’s list of investigational immune-oncological treatments that have the capacity to improve the lives of cancer patients.

    He added that JTX-1811 was complementary to the company’s other treatment candidates for cancer, and that, it had the potential to become a new class of treatment for haematological malignancies’ as well as for the treatment of solid tumours.

    The excitement around this stock stems from the fact that the partnership with Gilead has validated the viability of the JTX-1811. Investors are expecting that the program will lead to a major breakthrough and add to Jounce revenues in the near-term.

    What next for Jounce

    Since the agreement hints at an IND application in H1 of 2021, there is bound to be a sustained interest in this stock until them. Any major breakthrough on the program could add to the momentum. Looking at it from the perspective of the overall market, the stock’s fundamentals could see it gain a massive boost from the increased positive sentiment in the market.

    If a COVID-19 vaccine is approved soon, there is likely to be a major rally in the equity markets, and high potential stocks like Jounce stand to gain the most. That momentum has already started building up, and if Jounce holds on to today’s gains, it could mark the beginning of a significant uptrend.

    About Jounce Therapeutics Inc

    Jounce Therapeutics Inc is an immunotherapy company that makes cancer treatments. The company is based in Cambridge, Massachusetts.